Coverage
-
October 07, 2013
Australian medical product giant CSL Ltd. announced Monday that it will pay $64 million to escape a consolidated antitrust class action in which hospital groups claim it took part in a conspiracy to artificially hike the price of plasma-derivative protein therapies.
1 other articles on this case.
View all »